Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

BACKGROUND: Pixatimod (PG545) is a novel clinical-stage immunomodulatory agent capable of inhibiting the infiltration of tumor-associated macrophages (TAMs) yet also stimulate dendritic cells (DCs), leading to activation of natural killer (NK) cells. Preclinically, pixatimod inhibits heparanase (HPS...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Immunother Cancer
Autors principals: Hammond, Edward, Haynes, Nicole M., Cullinane, Carleen, Brennan, Todd V., Bampton, Darryn, Handley, Paul, Karoli, Tomislav, Lanksheer, Fleur, Lin, Liwen, Yang, Yiping, Dredge, Keith
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2018
Matèries:
Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6000956/
https://ncbi.nlm.nih.gov/pubmed/29898788
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s40425-018-0363-5
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars